新型小分子示踪剂68Ga-NY104 PET/CT评估von Hippel-Lindau综合征一例
Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging
阎歆淳 1霍力1
作者信息
- 1. 中国医学科学院北京协和医院核医学科,北京 100730
- 折叠
摘要
VHL(von Hippel-Lindau)综合征是一种罕见的常染色体显性遗传病.其临床表现复杂且多样,主要表现为视网膜、中枢神经系统、肾脏、胰腺等部位的多发肿瘤,患者常需进行全身多脏器评估.碳酸酐酶Ⅸ在VHL相关病变中普遍表达,68Ga-NY104 作为一种新型小分子示踪剂,可对碳酸酐酶Ⅸ阳性病灶进行全身成像.本文报道一例 32 岁女性VHL综合征患者,先后行18F-FDG PET/CT和68Ga-NY104 PET/CT评估病灶,结果发现后者在更多种类的病灶(包括肾脏、胰腺、肝转移病灶及小脑病灶)中存在摄取.本文就该患者相关病灶的评估过程展开讨论,以期为探索VHL综合征患者的"一站式"评估手段提供借鉴.
Abstract
VHL(von Hipple-Lindau)syndrome is a rare autosomal dominant genetic disease with com-plex and diverse clinical manifestations,which primarily presents as multiple tumors in the retina,central nerv-ous system,kidneys,pancreas,and other areas.Patients often require comprehensive multi-organ assessment.Carbonic anhydrase Ⅸ(CAⅨ)is ubiquitously expressed in VHL-related lesions,and 68Ga-NY104,a novel small-molecule tracer,can perform whole-body imaging of CAⅨ-positive lesions.This case report introduces a 32-year-old female patient with VHL syndrome who underwent sequential 18F-FDG PET/CT and 68Ga-NY104 PET/CT for lesion assessment.Notably,68Ga-NY104 PET/CT demonstrated uptake in a broader range of le-sions(including renal,pancreatic,hepatic metastatic lesions and cerebellar lesions).This article discusses the process of evaluating the relevant lesions in this patient,with the aim of exploring a"one-stop"evaluation tool for patients with VHL syndrome.
关键词
von/Hippel-Lindau综合征/68Ga-NY104/肾透明细胞癌/PET/CT/碳酸酐酶ⅨKey words
von Hippel-Lindau syndrome/68Ga-NY104/clear cell renal cell carcinoma/PET/CT/carbonic anhydraseⅨ引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据